NIOX Group (NIOX) Share Price, News & Analysis

Company Overview

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence.

Key Stats

• Today's Range: 73 to 73.60
• 50-Day Range: 67 to 76
• 52-Week Range: 53.40 to 80
• Volume: 11,422 shs
• Average Volume: 1.09 million shs
• Market Capitalization: £307.52 million
• P/E Ratio: 8,867.47
• Dividend Yield: 0.01%
• Price Target: GBX 90
• Consensus Rating: Buy

NIOX Group Stock Analysis - MarketRank™

NIOX Group scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Buy

Consensus Rating

NIOX Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

NIOX Group has a consensus price target of GBX 90, representing about 22.3% upside from its current price of GBX 73.60.

Amount of Analyst Coverage

NIOX Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NIOX Group is 8,867.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 280.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of NIOX Group is 8,867.47, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 80.36.

Price to Book Value per Share Ratio

NIOX Group has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NIOX.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

NIOX Group pays a meaningful dividend of 1.73%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

NIOX Group does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of NIOX Group is 120.48%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NIOX.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.37

News Sentiment

NIOX Group has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NIOX Group this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NIOX Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought £11,587.52 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

Only 4.89% of the stock of NIOX Group is held by insiders.

Percentage Held by Institutions

Only 7.56% of the stock of NIOX Group is held by institutions.

NIOX Stock Analysis - Frequently Asked Questions

How have NIOX shares performed this year?

NIOX Group's stock was trading at GBX 63 at the beginning of 2025. Since then, NIOX stock has increased by 16.8% and is now trading at GBX 73.60.

How were NIOX Group's earnings last quarter?

NIOX Group Plc (LON:NIOX) posted its quarterly earnings results on Tuesday, April, 1st. The company reported $2.27 earnings per share (EPS) for the quarter. NIOX Group had a trailing twelve-month return on equity of 13.29% and a net margin of 28.21%.

How do I buy shares of NIOX Group?

Shares of NIOX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of NIOX Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NIOX Group investors own include Petrofac (PFC), MICT (MICT), Chemring Group (CHG) and N Brown Group (BWNG).

Company Calendar

• Last Earnings: 4/01/2025
• Today: 9/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:NIOX
• CIK: N/A
• Web: investors.niox.com
• Phone: 44 18 6540 5560
• Fax: N/A
• Employees: 92
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NIOX Group: GBX 90
• High Price Target: GBX 90
• Low Price Target: GBX 90
• Potential Upside/Downside: +22.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.01
• Trailing P/E Ratio: 8,891.57
• Forward P/E Ratio: 63.30
• P/E Growth: N/A
• Net Income: £995.88 million
• Net Margins: 28.21%
• Pretax Margin: N/A
• Return on Equity: 13.29%
• Return on Assets: 3.95%

Debt

• Debt-to-Equity Ratio: 1.10
• Current Ratio: 6.31
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: £41.80 million
• Price / Sales: 7.38
• Cash Flow: GBX 6.58 per share
• Price / Cash Flow: 11.21
• Book Value: GBX 18.03 per share
• Price / Book: 4.09

Miscellaneous

• Outstanding Shares: 417,826,000
• Free Float: N/A
• Market Cap: £308.36 million
• Optionable: Not Optionable
• Beta: 0.92